- Home
- IRS vs SNDX Comparison
IRS vs SNDX Comparison
Compare IRS & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRS
- SNDX
- Stock Information
- Founded
- IRS 1943
- SNDX 2005
- Country
- IRS Argentina
- SNDX United States
- Employees
- IRS N/A
- SNDX N/A
- Industry
- IRS Homebuilding
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- IRS Real Estate
- SNDX Health Care
- Exchange
- IRS Nasdaq
- SNDX Nasdaq
- Market Cap
- IRS 873.6M
- SNDX 974.9M
- IPO Year
- IRS 1994
- SNDX 2016
- Fundamental
- Price
- IRS $14.62
- SNDX $13.34
- Analyst Decision
- IRS Strong Buy
- SNDX Strong Buy
- Analyst Count
- IRS 1
- SNDX 10
- Target Price
- IRS $12.62
- SNDX $36.20
- AVG Volume (30 Days)
- IRS 148.1K
- SNDX 2.0M
- Earning Date
- IRS 05-06-2025
- SNDX 05-07-2025
- Dividend Yield
- IRS 11.32%
- SNDX N/A
- EPS Growth
- IRS N/A
- SNDX N/A
- EPS
- IRS N/A
- SNDX N/A
- Revenue
- IRS $325,094,048.00
- SNDX $23,680,000.00
- Revenue This Year
- IRS N/A
- SNDX $286.51
- Revenue Next Year
- IRS N/A
- SNDX $120.86
- P/E Ratio
- IRS N/A
- SNDX N/A
- Revenue Growth
- IRS N/A
- SNDX N/A
- 52 Week Low
- IRS $8.21
- SNDX $9.66
- 52 Week High
- IRS $17.67
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- IRS 55.31
- SNDX 55.49
- Support Level
- IRS $13.63
- SNDX $10.81
- Resistance Level
- IRS $14.65
- SNDX $11.61
- Average True Range (ATR)
- IRS 0.99
- SNDX 1.04
- MACD
- IRS 0.18
- SNDX 0.25
- Stochastic Oscillator
- IRS 81.38
- SNDX 84.99
About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segment includes Shopping Malls; Offices; Sales and Developments; Hotels and others. It generates maximum revenue from the Shopping Malls segment. The Shopping Malls segment comprised of lease and service revenues related to rental of commercial space and other spaces in the shopping malls of the company.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.